290 related articles for article (PubMed ID: 16445845)
1. In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Prentice AG; Glasmacher A; Djulbegovic B
Br J Haematol; 2006 Mar; 132(5):656-8; author reply 658-9. PubMed ID: 16445845
[No Abstract] [Full Text] [Related]
2. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Glasmacher A; Prentice AG
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
[TBL] [Abstract][Full Text] [Related]
4. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Huijgens PC; Simoons-Smit AM; van Loenen AC; Prooy E; van Tinteren H; Ossenkoppele GJ; Jonkhoff AR
J Clin Pathol; 1999 May; 52(5):376-80. PubMed ID: 10560360
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Morgenstern GR; Prentice AG; Prentice HG; Ropner JE; Schey SA; Warnock DW
Br J Haematol; 1999 Jun; 105(4):901-11. PubMed ID: 10554799
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis and aspergillosis--has the principle been proven?
De Pauw BE; Donnelly JP
N Engl J Med; 2007 Jan; 356(4):409-11. PubMed ID: 17251538
[No Abstract] [Full Text] [Related]
10. [Prevention of mycotic infections in oncology patients with regard to the toxicity of antimycotic agents].
Doubek M; Mayer J; Horký D; Doubek J; Rácil Z; Vorlícek J
Vnitr Lek; 2002 Mar; 48(3):248-54. PubMed ID: 11968587
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole prophylaxis in hematologic cancer.
van Nieuwkoop C; van Dissel JT
N Engl J Med; 2007 May; 356(21):2215; author reply 2215-8. PubMed ID: 17526089
[No Abstract] [Full Text] [Related]
12. A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy.
Wang CY; Wu BY; Guo KY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Apr; 23(4):389-90. PubMed ID: 12697487
[TBL] [Abstract][Full Text] [Related]
13. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole prophylaxis in hematologic cancer.
Weiler S; Bellmann R
N Engl J Med; 2007 May; 356(21):2214; author reply 2215-8. PubMed ID: 17522407
[No Abstract] [Full Text] [Related]
15. [Prophylaxis of fungal infections in haematological patients: contra].
Schwartz S
Dtsch Med Wochenschr; 2010 Sep; 135(38):1871. PubMed ID: 20842608
[No Abstract] [Full Text] [Related]
16. Systemic fungal infections: major problems in cancer patients.
Powles RL; Mehta J
Indian J Cancer; 1994 Sep; 31(3):180-4. PubMed ID: 8557296
[TBL] [Abstract][Full Text] [Related]
17. [Prophylaxis of fungal infections in haematological patients: pro].
Glass B
Dtsch Med Wochenschr; 2010 Sep; 135(38):1870. PubMed ID: 20842607
[No Abstract] [Full Text] [Related]
18. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
Rogers TR; Slavin MA; Donnelly JP
Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
[TBL] [Abstract][Full Text] [Related]
19. Strategies for managing systemic fungal infection and the place of itraconazole.
Potter M
J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
de Vries R; Daenen S; Tolley K; Glasmacher A; Prentice A; Howells S; Christopherson H; de Jong-van den Berg LT; Postma MJ
Pharmacoeconomics; 2008; 26(1):75-90. PubMed ID: 18088160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]